Morgan Stanley’s Transphorm, Inc. Common Stock TGAN Stock Holding History

Morgan Stanley’s Portfolio TGAN Stock Details TGAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-54,913	Closed	-$270K	–	8002
2024 Q1	$270K	Sell	54,913 -12,682	-19%	-$60.2K	﹤0.01%	5607
2023 Q4	$247K	Buy	67,595 +36,820	+120%	+$101K	﹤0.01%	5618
2023 Q3	$68.3K	Buy	30,775 +7,993	+35%	+$22.3K	﹤0.01%	6036
2023 Q2	$77.5K	Buy	22,782 +6,452	+40%	+$23.3K	﹤0.01%	6050
2023 Q1	$65.2K	Buy	16,330 +5,671	+53%	+$25K	﹤0.01%	6185
2022 Q4	$58K	Buy	10,659 +2,930	+38%	+$17.2K	﹤0.01%	6228
2022 Q3	$39K	Buy	7,729 +2,738	+55%	+$13.5K	﹤0.01%	6521
2022 Q2	$19K	Sell	4,991 -9,421	-65%	-$60.2K	﹤0.01%	7013
2022 Q1	$102K	Buy	+14,412	New	+$101K	﹤0.01%	6299

Morgan Stanley's TGAN Position: Q2 2024 in Review

Morgan Stanley sold out of Transphorm, Inc. Common Stock (TGAN) in Q2 2024, closing a stake of 54,913 shares — an estimated $270K sold.

Morgan Stanley first reported a position in TGAN in Q1 2022 and held it in 9 quarters. The position peaked at $270K in Q1 2024. 0 funds tracked by Wall St. Rank hold TGAN as of Q2 2024.

Morgan Stanley reported no remaining Transphorm, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Morgan Stanley sold 54,913 Transphorm, Inc. Common Stock shares in Q2 2024, an estimated $270K.
Morgan Stanley first reported a position in Transphorm, Inc. Common Stock in Q1 2022 and held it in 9 quarters.
Morgan Stanley's Transphorm, Inc. Common Stock position peaked at $270K in Q1 2024.
0 funds tracked by Wall St. Rank held Transphorm, Inc. Common Stock as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.